1stOncology™: Cancer Intelligence Service – Page 6115 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Cue Biopharma to Host Business Update Call and Webcast

On November 7, 2022 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported that it will host a conference call and webcast to provide a business update on Monday, November 14, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Company’s website (Press release, Cue Biopharma, NOV 7, 2022, View Source [SID1234623288]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Members of the Cue Biopharma executive management team will provide an update and summary of the data presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 37th Annual Meeting (SITC 2022) highlighting the Company’s ongoing clinical trials evaluating its lead interleukin 2 (IL-2)-based biologic, CUE-101, as a monotherapy and in combination with pembrolizumab (KEYTRUDA) for patients with recurrent/metastatic HPV+ head and neck cancer. The company will also provide an update on its second clinical candidate from the CUE-100 series, CUE-102, targeting WT1 expressing cancers.

Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day

On November 7, 2022 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, reported that Company’s Management will participate in a presentation and one-on-one investor meetings at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day, to be held in-person in New York, NY from November 14-15, 2022 (Press release, Selecta Biosciences, NOV 7, 2022, View Source [SID1234623286]).

Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day

To schedule a meeting with the Company, please contact your Guggenheim representative.

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

argenx to Present at Upcoming Investor Conferences

On November 7, 2022 argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, reported that members of management will participate in several upcoming investor conferences in November (Press release, argenx, NOV 7, 2022, View Source [SID1234623285]):

Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day. Fireside chat on Monday, November 14, 2022 at 11:20 a.m. ET in New York, NY.

Stifel 2022 Healthcare Conference. Fireside chat on Tuesday, November 15, 2022 at 4:45 p.m. ET in New York, NY.

Jefferies London Healthcare Conference. Management will participate in investor meetings on Wednesday, November 16, 2022 in London, UK.

Evercore ISI 5th Annual HealthCONx Conference. Virtual fireside chat on Tuesday, November 29, 2022 at 10:55 a.m. ET.

Piper Sandler 34th Annual Healthcare Conference. Fireside chat on Wednesday, November 30, 2022 at 1:00 p.m. ET in New York, NY.

Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors.

AMPLIA APPOINTS DR CHRISTOPHER BURNS AS CEO AND MANAGING DIRECTOR

On November 7, 2022 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), a company developing new drug candidates for the treatment for cancer and fibrosis, reported the appointment of Christopher Burns Ph.D. as Chief Executive Officer, and Managing Director starting Dec 5th 2022 (Press release, Amplia Therapeutics, NOV 7, 2022, View Source;[email protected] [SID1234623284]).

Dr Burns is a founder of Amplia and has served as a non-executive member of the Board of Directors. Dr Burns has over 30 years’ experience in drug discovery and development and has served in executive level positions, including as CEO, for a number of public and private biotechnology companies. Dr Burns’ deep experience in cancer biology and kinase inhibitor development has contributed to advancement of multiple clinical candidates and he was the lead inventor of the drug momelotinib, a Janus kinase (JAK) inhibitor targeting myelofibrosis, which was recently acquired by GSK for US$1.9billion.

Amplia Chairman Dr Warwick Tong commented, "Chris is a highly experienced and accomplished oncology drug developer and brings a wealth of management expertise to the role. We are delighted he will step into the CEO role to continue to drive the clinical development of AMP945, Amplia’s lead Focal Adhesion Kinase inhibitor. He has been with the company since its inception, is a passionate advocate for Amplia’s technology, and has the leadership skills required to take Amplia through its next exciting stages of growth."

Dr Burns will succeed Dr John Lambert, who has served as Chief Executive Officer and Managing Director of the Company since June 2019 and February 2020, respectively. Dr Lambert and Dr Burns will work together over the coming months to ensure a seamless transition of operations.

Dr Burns said: "John Lambert has done a remarkable job and has guided the Company to this very exciting stage as we undertake our ACCENT trial of AMP945 in people with pancreatic cancer. I am excited to work with the excellent team at Amplia and continue to actively drive the ACCENT trial, whilst also progressing our preclinical work in other oncology indications, idiopathic pulmonary fibrosis, and with our second asset AMP886."

For the purposes of ASX Listing Rule 3.16.4, a summary of the material terms of Dr Burns’ Employment is included in Appendix 1.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery
Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

On November 7, 2022 Alaunos Therapeutics, Inc. ("Alaunos" or the "Company") (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company reported a poster presentation highlighting the potential of the Company’s human neoantigen T-cell receptor platform (hunTR) to expand its TCR Library (Press release, Alaunos Therapeutics, NOV 7, 2022, View Source [SID1234623283]). The data will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 37th Annual Meeting in Boston, Massachusetts from November 8-12, 2022.

"We are excited to present data demonstrating the ability of our proprietary hunTR platform to rapidly identify and validate neoantigen-reactive TCRs," commented Drew Deniger, Ph.D., Vice President, Research & Development. "By leveraging hunTR, our aim is to efficiently expand our TCR-T Library Phase 1/2 program with new, proprietary TCRs. This will enable us to broaden the pool of eligible patients who could benefit from our non-viral TCR-T cell therapies. We look forward to expanding our application of hunTR for additional shared KRAS, TP53, and EGFR mutations and rapidly take novel TCR candidates from the lab through to clinical translation."

hunTR is a high-throughput screening process that uses state-of-the-art bioinformatics and next generation sequencing to interrogate and deconvolute thousands of single T cells simultaneously. In the study, Alaunos evaluated ~525,000 TCR+HLA+neoantigen combinations in nine patients across colorectal, endometrial and breast cancers. All patients screened had at least one detectable neoantigen-reactive TCR, including one shared KRAS-Q61H mutation and 21 personal mutations. Of these, 78% were restricted by HLA Class II while 22% were restricted by HLA Class I. A median reactive hit rate of 13% was achieved per patient with an average of three unique neoantigen specificities. In subsequent patients screened only for KRAS mutations, multiple patients had TCRs reactive to KRAS-G12V, further demonstrating the ability of hunTR to discover exclusively owned hotspot mutation-reactive TCRs that could be added to the clinical library. The Company plans to continue to expand the application of hunTR to screen for additional shared KRAS, TP53, and EGFR mutations to rapidly advance new TCR library candidates from the lab through to clinical translation. In addition, hunTR may be suitable for personalized TCR-T therapies, enabling mutation-targeted cell therapy for most solid tumor cancers.